Tirzepatide Surges, Overtakes Older Drugs in Diabetes, Obesity Care

Researchers have used the US launch of tirzepatide, a dual glucagon-like peptide-1 receptor agonist (GLP-1 RA) and glucose-dependent insulinotropic polypeptide receptor agonist, as the dividing point to study trends in the use of glucose-lowering medications (GLMs) and weight-lowering medications (WLMs) using commercial insurance claim data.